Variant call concordance between two laboratory-developed, solid tumor targeted genomic profiling assays using distinct workflows and sequencing instruments

Experimental and Molecular Pathology

Volumn 102, Issue 2, 2017, Pages 215-218

  Hampel, Ken J ^a   de Abreu, Francine B ^b   Sidiropoulos, Nikoletta ^a   Peterson, Jason D ^b   Tsongalis, Gregory J ^b  

^a FLETCHER ALLEN HEALTH CARE   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Amplicon sequencing; Hybrid capture sequencing; Laboratory developed tests; Massively parallel DNA sequencing; Solid tumor genomic profiling

Indexed keywords

ARTICLE; CLINICAL LABORATORY; CONTROLLED STUDY; DNA HYBRIDIZATION; DNA SEQUENCE; EXON; GENE SEQUENCE; GENOMICS; HUMAN; HUMAN TISSUE; INTRON; MEDICAL DEVICE; RELIABILITY; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; TARGETED GENOMIC PROFILING; ALLELE; GENE EXPRESSION PROFILING; GENETICS; HIGH THROUGHPUT SEQUENCING; ISOLATION AND PURIFICATION; NEOPLASM; NUCLEIC ACID HYBRIDIZATION; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION STUDY;

DNA;

ALLELES; DNA, NEOPLASM; EXONS; GENE EXPRESSION PROFILING; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INTRONS; NEOPLASMS; NUCLEIC ACID HYBRIDIZATION; POLYMORPHISM, SINGLE NUCLEOTIDE; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

EID: 85012164933     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2017.02.002     Document Type: Article

References (27)

1. Aziz, N., et al. College of American Pathologists' laboratory standards for next-generation sequencing clinical tests. Arch. Pathol. Lab. Med. 139 (2015), 481–493.
2. Brower, V., NCI-MATCH pairs tumor mutations with matching drugs. Nat. Biotechnol. 33 (2015), 790–791.
3. Chang, F., Li, M.M., Clinical application of amplicon-based next-generation sequencing in cancer. Cancer Genet. 206 (2013), 413–419.
4. Cheng, D.T., et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 17 (2015), 251–264.
5. Cottrell, C.E., et al. Validation of a next-generation sequencing assay for clinical molecular oncology. J Mol Diagn. 16 (2014), 89–105.
6. de Abreu, F.B., et al. Effective quality management practices in routine clinical next-generation sequencing. Clin. Chem. Lab. Med. 54 (2016), 761–771.
7. Elisei, R., et al. RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. J. Clin. Endocrinol. Metab. 89 (2004), 3579–3584.
8. Froyen, G., et al. Validation and application of a custom-designed targeted next-generation sequencing panel for the diagnostic mutational profiling of solid tumors. PLoS One, 11, 2016, e0154038.
9. Gargis, A.S., et al. Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat. Biotechnol. 30 (2012), 1033–1036.
10. Goodwin, S., et al. Coming of age: ten years of next-generation sequencing technologies. Nat. Rev. Genet. 17 (2016), 333–351.
11. Hagemann, I.S., et al. Design of targeted, capture-based, next generation sequencing tests for precision cancer therapy. Cancer Genet. 206 (2013), 420–431.
12. Loman, N.J., et al. Performance comparison of benchtop high-throughput sequencing platforms. Nat. Biotechnol. 30 (2012), 434–439.
13. Machens, A., et al. Clinical relevance of RET variants G691S, L769L, S836S and S904S to sporadic medullary thyroid cancer. Clin. Endocrinol. 76 (2012), 691–697.
14. McNeil, C., NCI-MATCH launch highlights new trial design in precision-medicine era. J. Natl. Cancer Inst., 107, 2015.
15. Mendez, P., et al. Comprehensive evaluation and validation of targeted next-generation sequencing performance in two clinical laboratories. Int. J. Oncol. 49 (2016), 235–242.
16. Pfeifer, J.D., Clinical next generation sequencing in cancer. Cancer Genet. 206 (2013), 409–412.
17. Pritchard, C.C., et al. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J Mol Diagn. 16 (2014), 56–67.
18. Quail, M.A., et al. A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genomics, 13, 2012, 341.
19. Rehm, H.L., et al. ACMG clinical laboratory standards for next-generation sequencing. Genet. Med. 15 (2013), 733–747.
20. Samorodnitsky, E., et al. Comparison of custom capture for targeted next-generation DNA sequencing. J Mol Diagn. 17 (2015), 64–75.
21. Sharma, M.K., et al. Clinical genomicist workstation. AMIA Jt. Summits Transl. Sci. Proc. 2013 (2013), 156–157.
22. Singh, R.R., et al. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J. Mol. Diagn. 15 (2013), 607–622.
23. Sosonkina, N., et al. Kinome sequencing reveals RET G691S polymorphism in human neuroendocrine lung cancer cell lines. Genes Genomics. 36 (2014), 829–841.
24. State, N.Y., “Next Generation” Sequencing (NGS) Guidelines for Somatic Genetic Variant Detection. New York State, 2015.
25. Strom, S.P., Current practices and guidelines for clinical next-generation sequencing oncology testing. Cancer Biol. Med. 13 (2016), 3–11.
26. Tsongalis, G.J., et al. Routine use of the Ion Torrent AmpliSeq Cancer Hotspot Panel for identification of clinically actionable somatic mutations. Clin. Chem. Lab. Med. 52 (2014), 707–714.
27. Wong, K.M., et al. Unraveling the genetics of cancer: genome sequencing and beyond. Annu. Rev. Genomics Hum. Genet. 12 (2011), 407–430.